Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Blood Collection Tubes Market
The Blood Collection Tubes Market is projected to grow from USD 10.0 billion in 2025 to USD 18.8 billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.5%. This expansion is driven by the rising prevalence of chronic diseases, increasing demand for advanced diagnostic procedures, and the growing adoption of automation in laboratory workflows. The market encompasses a diverse range of product types, including Serum Separating Tubes, Plasma Separation Tubes, Rapid Serum Tubes, Heparin Tubes, EDTA Tubes, and others, with materials spanning glass and plastics.
End users span diagnostic centers, healthcare centers, and research and development centers, while key regions include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Market size
Growth trajectory through 2035
Blood Collection Tubes Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Advancements in Tube Materials
- Manufacturers are increasingly adopting biocompatible and low-adsorption polymers to enhance sample integrity and reduce interference in diagnostic assays.
-
Development 02 Automation Integration
- The development of tubes compatible with automated analyzers and high-throughput systems is accelerating, driven by the need for efficiency and reduced manual errors.
-
Development 03 Regulatory Updates
- Stricter regulatory frameworks, such as those imposed by the FDA and CE marking authorities, are compelling manufacturers to innovate and improve product efficacy to meet evolving standards.
-
Development 04 Sustainability Focus
- The industry is witnessing a shift toward biodegradable and recyclable blood collection tubes, reflecting growing environmental consciousness and regulatory pressures.
Emerging opportunities added
- Personalized medicine and precision diagnostics The shift toward tailored diagnostic solutions creates demand for specialized blood collection tubes with enhanced stability and minimal interference in downstream assays.
- Integration with laboratory automation Compatibility with automated analyzers and high-throughput systems presents opportunities for manufacturers to develop tubes optimized for seamless workflow integration.
- Emerging markets and healthcare expansion Rapidly growing healthcare infrastructure in regions such as Asia-Pacific and Latin America offers untapped potential for market penetration and revenue growth.
- Sustainability and eco-friendly solutions The development of biodegradable and recyclable blood collection tubes aligns with evolving regulatory and environmental standards, appealing to environmentally conscious stakeholders.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- volume testing and regulatory compliance requirements
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory hurdles
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Advancements in Tube Materials: Manufacturers are increasingly adopting biocompatible and low-adsorption polymers to enhance sample integrity and reduce interference in diagnostic assays
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 98-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Blood Collection Tubes Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of based testing, these tubes facilitate rapid clot formation and serum separation, throughput laboratories holds the largest share, and how do the growth rates diverge?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of chronic diseases) and top restraints (led by Regulatory hurdles), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of chronic diseases The growing burden of conditions such as diabetes, cardiovascular disorders, and infectious diseases necessitates frequent blood testing, driving demand for reliable blood collection tubes.
- Technological advancements in tube materials Innovations in biocompatible, low-adsorption materials and manufacturing processes improve sample integrity and reduce contamination risks.
- Expansion of laboratory infrastructure Increasing investments in centralized laboratories and high-throughput testing systems create robust demand for standardized blood collection devices.
- Regulatory compliance and biosafety standards Stricter regulatory frameworks mandate stringent quality standards for diagnostic consumables, incentivizing manufacturers to innovate and improve product efficacy.
- Adoption of automation in phlebotomy workflows The integration of closed-system blood collection and automation platforms streamlines sample handling, reduces manual errors, and enhances operational efficiency.
Restraints
Holding it back
- Regulatory hurdles Approval timelines for new products and compliance with evolving standards may extend time-to-market and increase operational costs.
- Supply chain vulnerabilities Component shortages and logistical challenges, particularly in raw materials like plastics and anticoagulants, can disrupt production and inflate costs.
- High cost of advanced materials The adoption of innovative, biocompatible materials and automation-compatible tubes may pose affordability challenges for smaller laboratories and healthcare providers.
- Infection control and biosafety concerns Ensuring sterility and preventing contamination in blood collection processes remain critical challenges, especially in resource-limited settings.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of chronic diseases | +2.9% | Global | 2025–2035 |
| Technological advancements in tube materials | +1.8% | Global | 2025–2035 |
| Expansion of laboratory infrastructure | +1.4% | Global | 2025–2035 |
| Regulatory compliance and biosafety standards | +1.0% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory hurdles | −1.2% | Global | 2025–2029 |
| Supply chain vulnerabilities | −0.8% | Global | 2025–2029 |
| High cost of advanced materials | −0.6% | Global | 2025–2029 |
Total 21 Serum Separating 29% Plasma Separatio 24% Rapid Serum Tube 19% Heparin Tubes 14% EDTA Tubes 10% Others 5% The Blood Collection Tubes Market is segmented by product type, material type, end user, and region.
Revenue share by type · 2025 base year
% OF $10.00 BN BLOOD COLLECTION TUBES MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $10.00 Bn Blood Collection Tubes Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
based testing, these tubes facilitate rapid clot formation and serum separation
-
throughput laboratories
By end-user industry
-
volume testing and regulatory compliance requirements
-
chart
-
template="treemap" data
-
palette="muted_green">
-
size="15" fill="#0f172a" text
-
anchor="middle" font
-
weight="bold">Regional Coverage
-
size="11" fill="white" text
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~37.0% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The Blood Collection Tubes Market is moderately consolidated, with a mix of global leaders and regional players competing for market share. Key companies leverage strategic investments in R&D, quality assurance, and global distribution networks to maintain their positions.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the market size for the blood collection tubes market?
The global Blood Collection Tubes market is anticipated to grow from USD 2.04 Billion in 2023 to USD 3.34 Billion by 2030, at a CAGR of 7.3% during the forecast period. -
• Which region is domaining in the blood collection tubes market?
North america accounted for the largest market in the Blood Collection Tubes market. North america accounted for the 38 % percent market share of the global market value. -
• Who are the major key players in the blood collection tubes market?
Becton, Dickinson and Company (BD), Terumo Corporation, QIAGEN N.V., Greiner Bio-One International GmbH, Sarstedt AG & Co. KG, Thermo Fisher Scientific Inc., FL Medical S.r.l. -
• What are the new trends in the blood collection tubes market?
Plastic blood collection tubes, made from materials such as polyethylene or polypropylene, have been gaining popularity due to their durability, reduced risk of breakage, and convenience. Plastic tubes also offer advantages in terms of cost and weight. There has been a trend toward the development of specialized blood collection tubes designed for specific diagnostic purposes. For example, tubes with additives tailored for molecular diagnostics, genomic testing, or specialized biomarker analysis.
The Blood Collection Tubes Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.